好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2008 Annual Meeting | Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurologic Disease

Saturday 04/19/08
09:00 AM - 12:45 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Michael Glantz, MD, FAAN
Participants should be able to describe the currently available classes of immunosuppressive and myelosuppressive agents, their neurologic and non-neurologic toxicities, and the practical aspects of their administration; explain the rationale and optimum strategies for the use of these agents in a wide spectrum of primary and secondary nervous system disorders, including demyelinating and neuromuscular diseases; establish a safe and efficient office-based program for the use of immunosuppressive and myelosuppressive therapies in patients with nervous system diseases; develop algorithms for patient selection, informed consent, treatment, and monitoring; and apply standardized metrics for assessing treatment outcome.
No CME available
Patient Care & Procedural Skills, Professionalism, Medical Knowledge, Systems-based Practice
Advanced
Practitioner, Fellow, Academician, Resident, Nurse
Event Timeline
09:00 AM - 09:20 AM Immunosuppressive Therapy for Neuromuscular Disease: How I Do It
Mark S. Freedman, MD, FAAN
09:20 AM - 09:40 AM Immunosuppressive Therapy for Neuromuscular Disease: How I Do It
Marinos C. Dalakas, MD, FAAN
09:40 AM - 10:15 AM Immunosuppression in the Office: Making Poisons Palatable
Michael Glantz, MD, FAAN
10:15 AM - 10:50 AM Ethical Immunosuppression: Doing the Math and Explaining the Results
Samuel Wiebe, MD
10:50 AM - 11:05 AM Break
11:05 AM - 11:40 AM Immunosuppression in the Office: How to Be Safe and Efficient
Camilo E. Fadul, MD, FAAN
11:40 AM - 12:05 PM Case Presentations: Demyelinating Disease
Mark S. Freedman, MD, FAAN
12:05 PM - 12:30 PM Case Presentations: Neuromuscular Disease
Marinos C. Dalakas, MD, FAAN
12:30 PM - 12:45 PM Questions and Answers
Faculty Disclosures
Michael Glantz, MD, FAAN No disclosure on file
Marinos C. Dalakas, MD, FAAN Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx,. Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.
Camilo E. Fadul, MD, FAAN No disclosure on file
Samuel Wiebe, MD Dr. Wiebe has a non-compensated relationship as a Past President with International League Against Epilepsy that is relevant to AAN interests or activities.
Mark S. Freedman, MD, FAAN Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.